Cooperation with China in Biotechnology
Representatives from MEDINA and Granada City Hall recently travelled to China to attend the 13th EU-China Seminar on Regional Policy Cooperation. The aim of the event, held in Zhengzhou, Henan province, is to promote institutional, scientific and economic cooperation between the two regions. MEDINA is a drug discovery research organisation based in the Granada Health Science Technological Park (PTS).
The EU-China Seminar is an innovative event designed to provide a meeting place for technology-focused companies from the two regions. Participants travelled from Granada and nine other European cities to take part, and some 200 Chinese institutions also attended. Representatives from China's Department of Regional Economy of the National Development and Reform Commission and the Directorate-General for Regional and Urban Policy of the European Commission were also in attendance.
The seminar gave MEDINA the opportunity to outline its biotechnology innovation model, providing a launch pad for future meetings with Chinese organisations and businesses working in the sector. Granada's involvement in this top-level event is the result of the EU's International Urban Cooperation programme, which aims to enable cities from different parts of the world to link up and share solutions to common problems.
As part of this programme, Granada was selected as a Smart City to be paired with a number of Chinese cities. MEDINA's Business Manager, Diego Pozas, said that “thanks to this programme, this autumn one or two Chinese cities will visit the PTS and MEDINA's own headquarters to continue looking at potential collaboration projects.”
MEDINA is a public-private alliance between the Regional Government of Andalusia, pharmaceutical company Merck Sharp & Dohme (MSD) and the University of Granada. It specialises in discovering innovative therapies and compounds with biological properties to develop new drugs.
MEDINA recently joined the EU-OPENSCREEN network, a consortium of 24 European organisations from its seven founding European countries that has been granted the status of European Research Infrastructure Consortium (ERIC).
EU-OPENSCREEN's primary aim is to create a research infrastructure that meets the needs of academic institutions, research centres, biotechnology companies and the rest of the industry, which need such platforms to make progress in biological chemistry and carry out research into new molecular processes. EU-OPENSCREEN offers access to Europe's leading medicinal chemistry and drug screening platforms, as well as to libraries of compounds required for these studies.